Advanced in Angiosarcoma

Dr. Jacob D. Bitran

Hematology Oncology | Hematology | Oncology
Advocate Health And Hospitals Corporation
1775 Dempster St, 
Park Ridge, IL 
Accepting New Patients
Advanced in Angiosarcoma
Advocate Health And Hospitals Corporation
1775 Dempster St, 
Park Ridge, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jacob Bitran is a Hematologist Oncology specialist and a Hematologist in Park Ridge, Illinois. Dr. Bitran is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Non-Hodgkin Lymphoma, Breast Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Bitran is currently accepting new patients.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Advocate Lutheran General Hospital
Advocate Illinois Masonic Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

ADVOCATE HEALTH AND HOSPITALS CORPORATION
1775 Dempster St, Park Ridge, IL 60068
Other Locations
ADVOCATE HEALTH AND HOSPITALS CORPORATION
1775 W Ballard Rd, Geriatrics, Park Ridge, IL 60068
ADVOCATE HEALTH AND HOSPITALS CORPORATION
214 Mchenry Rd, Buffalo Grove, IL 60089
ADVOCATE HEALTH AND HOSPITALS CORPORATION
1775 Ballard Rd, Park Ridge, IL 60068
ADVOCATE HEALTH AND HOSPITALS CORPORATION
1700 Luther Ln, Park Ridge, IL 60068

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 5 Less Clinical Trials

23 Total Publications

Nationwide Trends and Disparities in End-of-Life Care for Acute Myeloid Leukemia: A 2019-2021 NIS Analysis of Palliative Care Utilization and Hospitalization Costs.
Nationwide Trends and Disparities in End-of-Life Care for Acute Myeloid Leukemia: A 2019-2021 NIS Analysis of Palliative Care Utilization and Hospitalization Costs.
Journal: The American journal of hospice & palliative care
Published: June 24, 2025
Similar Doctors
Pamela E. Kaiser
Distinguished in Angiosarcoma
Dr. Pamela E. Kaiser
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Pamela E. Kaiser
Hematology | Oncology

Advocate Lutheran General Cancer Institute

1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
 (1.9 miles away)
847-268-8200
Languages Spoken:
English
See accepted insurances

Pamela Kaiser is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Kaiser is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy.

Distinguished in Angiosarcoma
Dr. Regina M. Stein
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Regina M. Stein
Hematology | Oncology
676 N St Clair St Ste 2140, Arkes Pavilion, 
Chicago, IL 
 (15.5 miles away)
866-587-4322
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Regina Stein is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Stein has been practicing medicine for over 24 years and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Breast Cancer.

Distinguished in Angiosarcoma
Dr. Lisa E. Flaum
Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Lisa E. Flaum
Hematology | Oncology
250 E Superior St Ste 5-2261, Prentice Women's Hospital, 
Chicago, IL 
 (15.2 miles away)
866-587-4322
Experience:
27+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lisa Flaum is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Flaum has been practicing medicine for over 27 years and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bitran's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile